Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) exhibits extensive intratumoral heterogeneity that contributes to therapeutic resistance and disease recurrence. However, conventional bulk analyses often obscure the molecular and functional diversity of individual tumor cell populations, limiting the identification of rare drug-resistant populations. Here, we present a high-resolution, drop-on-demand inkjet bioprinting platform for generating single cell-derived PDAC organoids to systematically investigate clonal heterogeneity. Using this platform, we generated over 600 organoids and characterized substantial variations in morphology, growth kinetics, protein expression, and chemotherapeutic responses. Transcriptomic profiling of 30 individual organoids further revealed pronounced molecular heterogeneity, even among organoids assigned to the same morphological subtype. Notably, morphology-based classification into classical and basal-like subtypes did not consistently correspond to transcriptomic signatures, demonstrating that morphological similarity does not necessarily reflect molecular similarity. Furthermore, individual organoids exhibited heterogeneous responses to gemcitabine and nab-paclitaxel, including highly resistant organoids whose responses were obscured by subtype-averaged analyses. Together, these findings establish an inkjet-based clonal organoid platform that integrates controlled single-cell deposition with molecular profiling and longitudinal drug-response analysis, enabling systematic characterization of morphological, molecular, and functional heterogeneity at the individual organoid level.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: